Ignite Creation Date:
2024-05-06 @ 7:38 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06087263
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2023-10-12
Brief Title:
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets KIT Exon 17 18 or 14 Mutation and SDHB Deficient GIST in the Post-imatinib Second-line Setting
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Organization Data
Organization:
MD Anderson Cancer Center
Class:
OTHER
Study ID:
2023-0390
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MD Anderson Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bayer | INDUSTRY |